Elite Pharmaceuticals Inc. (OTCMKTS:ELTP – Get Free Report) saw an uptick in trading volume on Monday . 351,820 shares were traded during trading, an increase of 146% from the previous session’s volume of 142,816 shares.The stock last traded at $0.4820 and had previously closed at $0.50.
Elite Pharmaceuticals Price Performance
The stock has a market cap of $503.83 million, a P/E ratio of 46.94 and a beta of 0.32. The company has a quick ratio of 6.34, a current ratio of 8.04 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $0.54 and its two-hundred day simple moving average is $0.59.
Elite Pharmaceuticals Company Profile
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.
Featured Stories
- Five stocks we like better than Elite Pharmaceuticals
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- You Still Think Silver’s a Joke? Watch What Happens Next.
- This stock gets a 94 out of 100
- Punch these codes into your ordinary brokerage account
Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
